Equities

Singular Genomics Systems Inc

OMIC:NAQ

Singular Genomics Systems Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)16.30
  • Today's Change0.08 / 0.49%
  • Shares traded21.87k
  • 1 Year change+46.89%
  • Beta1.3885
Data delayed at least 15 minutes, as of Sep 20 2024 15:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Singular Genomics Systems Inc fell by 59.14m. However, Cash Flow from Investing totalled 13.81m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 73.65m for operations while cash generated from financing totalled 696.00k.
Cash flow per share-35.77
Price/Cash flow per share--
Book value per share55.27
Tangible book value per share55.27
More ▼

Balance sheet in USDView more

Singular Genomics Systems Inc has a Debt to Total Capital ratio of 6.96%, a higher figure than the previous year's 4.64%.
Current ratio8.77
Quick ratio8.04
Total debt/total equity0.0748
Total debt/total capital0.0696
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.